Abstract：
:Local excision is an alternative approach to radical proctectomy for rectal cancer, but from an oncologic standpoint, it is a compromise, and its role remains controversial. Careful patient selection is essential because local excision is generally considered only for early rectal cancer with no evidence of nodal metastasis, parameters that can be predicted by clinical examination, and various radiologic modalities with variable accuracy. In this review, we present the literature evaluating the oncologic adequacy of local excision, including transanal endoscopic microsurgery and the results of salvage surgery after local excision. An overview of local excision in the context of perioperative adjuvant therapies is included. Finally, we suggest a treatment algorithm for local excision in rectal cancer.
journal_name
Clin Colorectal Cancerjournal_title
Clinical colorectal cancerauthors
Kim E,Hwang JM,Garcia-Aguilar Jdoi
10.3816/CCC.2008.n.050subject
Has Abstractpub_date
2008-11-01 00:00:00pages
376-85issue
6eissn
1533-0028issn
1938-0674pii
S1533-0028(11)70446-7journal_volume
7pub_type
杂志文章,评审abstract：BACKGROUND:Treatment sequencing for patients with refractory metastatic colorectal cancer (mCRC) has been highly debated. The thymidine-based nucleoside trifluridine/tipiracil (TAS-102) and the multikinase inhibitor regorafenib have demonstrated clinical benefits in randomized phase III trials compared with placebo. Ho...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2018.05.012
更新日期：2018-12-01 00:00:00
abstract：BACKGROUND:Few clinical studies have investigated the association between neutrophil-lymphocyte ratio (NLR) and treatment with cetuximab-based chemotherapy in metastatic colorectal cancer (mCRC). The NLR may reflect immune cells modulating specific cytokine signals in the tumor microenvironment; however, which immune-r...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2018.08.002
更新日期：2018-12-01 00:00:00
abstract：:Approximately 40% of patients treated with curative intent for colorectal carcinoma eventually recur. In about one third of these patients, the lesion is localized and potentially resectable. Typically, the recurrence is characterized by findings on diagnostic imaging studies and may be accompanied by a rise in the se...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.3816/CCC.2001.n.012
更新日期：2001-08-01 00:00:00
abstract：BACKGROUND:5-Fluorouracil (5-FU) chemotherapy is associated with severe and unpredictable toxicity in a significant proportion of patients. 5,10-Methylenetetrahydrofolate and 5-fluorodeoxyuridine monophosphate bind to thymidylate synthase and together inhibit its function, resulting in cytotoxicity. We hypothesized tha...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2016.06.001
更新日期：2016-12-01 00:00:00
abstract：:This phase II study was designed to characterize the clinical activity of ISIS 3521 in patients with metastatic colorectal cancer (CRC). Sixteen patients with pretreated or refractory CRC were treated with ISIS 3521. Eleven patients were given a dose of 2.0 mg/kg per day, and 5 patients received 3.0 mg/kg per day give...
journal_title：Clinical colorectal cancer
pub_type： 临床试验,杂志文章
doi：10.3816/ccc.2004.n.026
更新日期：2004-11-01 00:00:00
abstract：:Replacing infusional 5-fluorouracil (5-FU) leucovorin (LV) with oral capecitabine would be more convenient to patients, because it would lead to reduced hospital chair time and infusion-related toxicities. Previous trials with oral capecitabine-based regimens (other than XELOX [capecitabine/oxaliplatin]) have failed t...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.3816/CCC.2006.n.044
更新日期：2006-11-01 00:00:00
abstract：:The standard in rectal cancer has been to add adjuvant radiation therapy to surgery in patients with stage II and III disease. Total mesorectal excision has led to lower local recurrence rates, and, if properly performed, may make adjuvant radiation unnecessary for certain stage II and III patients, such as T3 N0 pati...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.3816/CCC.2003.n.002
更新日期：2003-02-01 00:00:00
abstract：BACKGROUND:Similar epidemiologic characteristics suggest a common etiology for colon cancer (CC) and diverticular disease of the colon (DD). The relationship between the 2 diseases is still unclear, and the impact of DD in patients diagnosed with CC on disease-free survival (DFS) and overall survival (OS) is unknown. N...
journal_title：Clinical colorectal cancer
pub_type： 临床试验,杂志文章
doi：10.3816/ccc.2006.n.031
更新日期：2006-07-01 00:00:00
abstract：:Primary squamous cell colorectal carcinomas are uncommon, and their characteristics are not well known. They seem to occur most commonly in the fifth decade of life with a slight predominance for men. The most commonly reported anatomic locations are the rectum and the proximal colon. Clinical features and common diag...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.3816/CCC.2001.n.006
更新日期：2001-05-01 00:00:00
abstract：:Despite an armamentarium that is wide in range, scope of action, and target, chemotherapy has limited success in colorectal cancer (CRC). Novel approaches are needed to overcome tumor barriers to chemotherapy that includes an abnormal tumor vasculature constituting a poor drug delivery system. We have previously shown...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.3816/CCC.2009.n.025
更新日期：2009-07-01 00:00:00
abstract：BACKGROUND:Quinacrine plus a fluoropyrimidine has in vivo efficacy against metastatic colorectal cancer (mCRC). This phase 1b trial evaluated the combination of quinacrine plus capecitabine in patients with treatment-refractory mCRC. PATIENTS AND METHODS:Using a modified Simon accelerated titration design, adults with...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2020.08.003
更新日期：2020-08-19 00:00:00
abstract：:The use of adjuvant chemotherapy has improved survival in early-stage colon cancer. Ongoing adjuvant clinical trials are evaluating the addition of targeted therapies to standard chemotherapy regimen. Preliminary results with bevacizumab were disappointing. Also, cetuximab added to chemotherapy does not seem to be bet...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.3816/CCC.2010.n.039
更新日期：2010-12-01 00:00:00
abstract：INTRODUCTION:Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU. Given the additional benefit of oxaliplatin over FP alone in the management of color...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2018.09.006
更新日期：2019-03-01 00:00:00
abstract：PURPOSE:Capecitabine has shown similar efficacy to 5-fluorouracil (5-FU); a regimen containing 2 weeks of capecitabine/oxaliplatin (CapOx) has demonstrated noninferiority to infusional 5-FU/oxaliplatin/leucovorin (FOLFOX) for the treatment of metastatic colorectal cancer (mCRC). This phase II study explores the efficac...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.3816/CCC.2010.n.021
更新日期：2010-07-01 00:00:00
abstract：OBJECTIVE:The purposes of this study were to confirm the definite metastasis and micrometastasis rate of upward and lateral lymph nodes of mid-to-low rectal cancer at stage II and stage III, and to evaluate the feasibility and safety of laparoscopic radical correction combined with extensive lymphadenectomy and pelvic ...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2011.03.025
更新日期：2011-09-01 00:00:00
abstract：:Several anticancer therapies have been developed to block angiogenesis, a key mechanism in tumor growth and metastasis. The predominantly cytostatic action of these compounds makes an assessment of their clinical activities inadequate if based only on the reduction of the tumor dimensions, as this may not reflect thei...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clcc.2014.12.002
更新日期：2015-03-01 00:00:00
abstract：BACKGROUND:Screening protocols for colorectal cancer are broadly recommended and effective in reducing mortality. However, populations from different age groups can harbor distinct pathologic and molecular profiles that can also be influenced by screening and polyp resection, especially in older ages. PATIENTS AND MET...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2020.06.004
更新日期：2020-12-01 00:00:00
abstract：BACKGROUND:As more patients are screened for colorectal cancer a small but significant number of interval cancers develop after colonoscopy for colorectal cancer screening. MATERIALS AND METHODS:We reviewed records of 75,314 adult patients who underwent colonoscopy for screening or diagnostic purposes between 1998 and...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2014.11.001
更新日期：2015-03-01 00:00:00
abstract：:The discovery of the key role of the epidermal growth factor receptor (EGFR) and its downstream signaling effectors in the pathophysiology of colorectal cancer (CRC) has ushered in the clinical use of targeted therapies in the treatment of metastatic CRC (mCRC). The anti-EGFR monoclonal antibodies cetuximab and panitu...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clcc.2015.05.006
更新日期：2015-12-01 00:00:00
abstract：BACKGROUND:The prognostic value of tumor sidedness in metastatic colorectal cancer (CRC) has been established, but its impact on nonmetastatic disease remains unclear. Our study aimed to explore the prognostic effect of tumor sidedness by subgroup survival analyses, according to histology and tumor grade in stage I-IV ...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2018.10.005
更新日期：2019-03-01 00:00:00
abstract：:Thymidylate synthase (TS) is a key enzyme in the synthesis of 2'-deoxythymidine-5'-monophosphate, an essential precursor for DNA biosynthesis. For this reason, this enzyme is a critical target in cancer chemotherapy. As the first TS inhibitor in clinical use, 5-fluorouracil (5-FU) remains widely used for the treatment...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.3816/CCC.2002.n.003
更新日期：2002-02-01 00:00:00
abstract：BACKGROUND:Adenocarcinoma of the vermiform appendix is rare. It constitutes less than 0.5% of all gastrointestinal malignancies. Pathologically, appendiceal neoplasms are categorized into various subtypes depending on cell lineage. PATIENTS AND METHODS:We considered a case series of appendiceal invasive adenocarcinoma...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2014.11.003
更新日期：2015-03-01 00:00:00
abstract：UNLABELLED:Patients with colorectal cancer (CRC) and renal cell carcinoma (RCC) may be at risk for additional primary malignancies. A review of 101 patients with these concurrent diagnoses was performed. Forty-two percent of patients had 1 or more additional malignancies; none appeared to be associated with Lynch syndr...
journal_title：Clinical colorectal cancer
pub_type： 临床试验,杂志文章
doi：10.1016/j.clcc.2012.07.004
更新日期：2013-03-01 00:00:00
abstract：BACKGROUND:Köhne prognostic score is used to classify patients with metastatic colorectal cancer (mCRC) as high, intermediate, or low risk. Using data from 2 phase III trials, we analyzed survival in patients categorized according to Köhne prognostic category and virus-induced rapidly accelerated fibrosarcoma murine sa...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2017.09.006
更新日期：2018-03-01 00:00:00
abstract：:As new improvements in the treatment of colorectal cancer have become available, it has become important to understand the benefits of new therapies or the deleterious effects stemming from the increased risk of toxicity. In particular, a more rational approach to adjuvant chemotherapy for patients with stage II/III d...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.3816/ccc.2006.n.019
更新日期：2006-05-01 00:00:00
abstract：BACKGROUND:We performed a meta-analysis of previous reports evaluating the effect of mFIO (modified FOLFIRINOX; leucovorin, 5-fluorouracil, irinotecan, oxaliplatin) regimens in advanced pancreatic cancer. MATERIALS AND METHODS:We performed a meta-analysis of reported studies in PubMed, Scopus, and Web of Science (1950...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,meta分析
doi：10.1016/j.clcc.2018.03.007
更新日期：2018-09-01 00:00:00
abstract：:Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal cancer of teh gastrointestinal tract. They are characterized by the expression of KIT. Therapeutically, metastatic GISTs are effectively treated by imatinib, a tyrosine kinase inhibitor (TKI) with activity against KIT and platelet-derived growth f...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.3816/ccc.2006.s.005
更新日期：2006-11-01 00:00:00
abstract：INTRODUCTION:The aim of this study was to evaluate the efficacy and toxicity of molecular targeted agents plus chemotherapy compared with chemotherapy alone as second-line therapy for patients with metastatic colorectal cancer (mCRC). MATERIALS AND METHODS:We identified randomized controlled trials that compared molec...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,meta分析
doi：10.1016/j.clcc.2016.03.005
更新日期：2016-12-01 00:00:00
abstract：:To evaluate, from a US payer perspective, the cost-effectiveness of treatment strategies for metastatic colorectal cancer (mCRC), we performed a systematic review of published cost-effectiveness analyses. We identified 14 papers that fulfilled our search criteria and revealed varying levels of value among current trea...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clcc.2015.10.002
更新日期：2016-03-01 00:00:00
abstract：BACKGROUND:Anal squamous cell carcinoma (ASCC) is a rare, human papilloma virus-associated cancer. The purpose was to investigate the population-based incidence rates, age and gender distribution, and survival of ASCC. MATERIALS AND METHODS:All primary ASCC in 1987 to 2016 were identified in the Cancer Registry of Nor...
journal_title：Clinical colorectal cancer
pub_type： 杂志文章
doi：10.1016/j.clcc.2018.10.001
更新日期：2019-03-01 00:00:00
